Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Drop in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) saw a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 105,700 shares, a drop of 40.5% from the January 15th total of 177,500 shares. Based on an average daily volume of 134,400 shares, the short-interest ratio is currently 0.8 days. Approximately 0.2% of the shares of the company are short sold.

Institutional Trading of Xtant Medical

Hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC raised its stake in Xtant Medical by 15.0% during the fourth quarter. Renaissance Technologies LLC now owns 798,033 shares of the medical device company's stock worth $354,000 after acquiring an additional 103,825 shares in the last quarter. Geode Capital Management LLC grew its holdings in Xtant Medical by 70.2% in the third quarter. Geode Capital Management LLC now owns 515,006 shares of the medical device company's stock worth $348,000 after purchasing an additional 212,394 shares during the period. Finally, Evernest Financial Advisors LLC acquired a new position in shares of Xtant Medical during the third quarter worth approximately $27,000. 69.33% of the stock is owned by institutional investors and hedge funds.

Xtant Medical Stock Up 0.3 %

XTNT traded up $0.00 during mid-day trading on Monday, reaching $0.60. The stock had a trading volume of 121,651 shares, compared to its average volume of 45,930. The firm has a market capitalization of $83.21 million, a price-to-earnings ratio of -4.60 and a beta of 0.35. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12. Xtant Medical has a 52 week low of $0.33 and a 52 week high of $1.30.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.